Study summary
Osimertinib before surgery shrank tumors far more than chemotherapy alone
26%major pathologic response with osimertinib plus chemo, vs 2% with chemo
What was tested
Osimertinib with or without chemotherapy, or chemotherapy alone, before surgery for resectable stage II to IIIB EGFR-mutated lung cancer.
What they found
- Major pathologic response (little cancer left at surgery) was 26% with osimertinib plus chemo, 25% with osimertinib alone and 2% with chemo alone.
- Event-free survival data were still early.
What it means
Supports giving osimertinib before surgery; long-term survival results are still to come.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.